Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935282 · ClinicalTrials.gov registry record · NA
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
A NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 12
- Study locations
NCT03935282: Completed NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms, sponsored by Wake Forest University Health Sciences.
NCT03935282 is a NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 600 participants, above the 162-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (270% higher). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03935282, a NA study of Non-Hodgkin Lymphoma and Colorectal Neoplasms, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 12
- Study locations
Study Summary
The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in community oncology practices, using a group-randomized trial design (6 intervention practices and 6 usual care practices). Our central hypothesis is that the AH-HA tool will increase (1) cardiovascular health (CVH) discussions among survivors and oncology providers, (2) referrals and visits to primary care and cardiology (care coordination), and (3) cardiovascular (CV) risk reduction and health promotion activities compared to usual care.
Primary Outcome
Discussion of non-ideal cardiovascular health (CVH) factors (yes or no). CVH discussions will be defined as patient-reported discussions with their provider for any of the seven non-ideal CVH conditions identified for that patient. Conditions include CVH factors (cholesterol, blood pressure, glucose/hemoglobin A1c) and CVH behaviors (body mass index, smoking, diet, and physical activity). Measured using survivor survey (discussions, diet, and primary care) and EHR for other CVH factors.
Conditions Studied
Interventions
- OTHER AH-HA Tool in the EPIC EHR
Study Locations (12)
Missouri
- Saint Louis Cancer and Breast Institute-Ballwin - Ballwin
- Mercy Hospital Springfield - Springfield
- Mercy Hospital Saint Louis - St Louis
Pennsylvania
- Community Medical Center - Scranton
- Geisinger Wyoming Valley/Henry Cancer Center - Wilkes-Barre
Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis - Memphis
- Baptist Memorial Hospital for Women - Memphis
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Iowa
- Oncology Associates at Mercy Medical Center - Cedar Rapids
Oklahoma
- Mercy Hospital Oklahoma City - Oklahoma City
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Wisconsin
- ThedaCare Regional Cancer Center - Appleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-11-17 |
| Phase | NA |
What the finished NCT03935282 record still lists
NCT03935282 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 162-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (270% higher).
The record links to 6 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AH-HA Tool in the EPIC EHR is the first listed.
NCT03935282 lists 12 locations in 8 states (Missouri, Pennsylvania, Tennessee).
Frequently Asked Questions
What is clinical trial NCT03935282 about?
NCT03935282 is a clinical study titled "Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors". The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in commun...
What is the current status of trial NCT03935282?
This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2020-10-01. Estimated completion is 2025-11-17.
What conditions does trial NCT03935282 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Colorectal Neoplasms, Breast Neoplasm, Hodgkin Disease, Endometrial Neoplasms.
What interventions are being tested in trial NCT03935282?
The interventions under investigation include: AH-HA Tool in the EPIC EHR (OTHER).
Who is sponsoring clinical trial NCT03935282?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935282 being conducted?
This trial has 12 study locations across Arkansas, Iowa, Missouri, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03935282's enrollment target sits among peer trials
600 7th of 106 higher than 100 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
ACTIVE NOT RECRUITING · NA
-
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · NA
-
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
COMPLETED · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI